The Studio at Kendall Square

Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities

They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science

AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner

Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next ye

Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs

Servier's 'Golden Ticket' gave Deck Bio a place to work from at LabCentral and access to Servier's experts for advice. Jack and Irene discuss the benefits of this kind of

Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs

In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines,

Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th

Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have alr

MassBio's CEO Kendalle Burlin O'Connell shares the details of today's just published 2025 Industry Snapshot - a key barometer of the health of biotech not just in Massachusetts, but as an industry

She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more.

Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward

They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiv

Lisa Deschamps of AviadoBio and Richard Wilson of Astellas discuss the field of AAV gene therapy, and their partnership on AVB-101, an AAV gene therapy for frontotemporal dementia (FTD)

Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to the thalamus. They describe the u

Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses

Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, a

Elias Zerhouni and Andy Plump discuss the future of multispecific biologics

Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differen

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development a

Korro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discovery

Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work t

Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more

Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this y

The co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisors

In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel Pomeroy describes the history and goal

A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial

Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the w

Janssen's Elena Diez and Odyssey Therapeutics' Gary Glick share advice on success factors for pharma - biotech partnerships, and more

They discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful col

Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech

Biotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies. Plus, a warning about the currently

Transcriptional regulation in disease: opportunities, challenges, and the future

Cigall Kadoch, associate professor and HHMI Investigator, Dana-Farber Cancer Institute and Harvard Medical School, and scientific founder of Foghorn Therapeutics (NASDAQ:

A father and patient advocate discuss Canavan disease and a daughter's experience on a gene therapy clinical trial

Lauren Celano, a board member of the National Tay-Sachs & Allied Diseases Association, interviews Lee Greenwood about his family's experience with Canavan disease and how

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

For this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the possible range of edits, choosing the ri